Labrys Biologics is a private, venture-financed development stage biotechnology company focused on treatments for chronic migraine and episodic migraine
Labrys Biologics is a private, venture-financed development stage biotechnology company focused on treatments for chronic migraine and episodic migraine. It has developed RN-307, a Phase 2 ready anti-CGRP humanized monoclonal antibody for the treatment of chronic migraine.